Frequency Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
2023/08/05

* Frequency Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on August 7 (estimated).

*

* ​Refinitiv's mean analyst estimate for Frequency Therapeutics Inc is for a loss of 36 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Frequency Therapeutics Inc is $4​, above​ its last closing price of $0.73. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT IBES MET, SE %

E® ESTIMATE MISSED

Mar. 31 2023 -0.41 -0.42 -0.55 Missed -30.8

Dec. 31 2023 -0.57 -0.63 -0.49 Beat 22.3

Sep. 30 2022 -0.56 -0.57 -0.55 Beat 3.4​

Jun. 30 2022 -0.70 -0.67 -0.61 Beat 9.4

​​Mar. -0.62 -0.63 -0.67 Missed -5.5

31 2022

Dec. 31 2021 0.59 0.15 -0.62 Missed -506.8

Sep. 30 2021 -0.52 -0.57 -0.73 Missed -27.2

Jun. 30 2021 -0.51 -0.51 -0.52 Missed -2.3

This summary was machine generated August 5 at 02:07 GMT. All figures in US dollars unless otherwise stated.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10